As of Feb 12
| +0.18 / +6.16%|
The 4 analysts offering 12-month price forecasts for Endocyte Inc have a median target of 10.50, with a high estimate of 12.00 and a low estimate of 9.00. The median estimate represents a +238.71% increase from the last price of 3.10.
The current consensus among 5 polled investment analysts is to Buy stock in Endocyte Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.